Role of intranasal insulin in the management of post- COVID -19 Olfactory dysfunction | ||||
| Minia Journal of Medical Research | ||||
| Articles in Press, Accepted Manuscript, Available Online from 01 July 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2024.292871.1715 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mostafa Ismail1; soad ali2; Abd El Rehim singer3; Amr Adel Abdel Monem  4; Rasha Ahmed Abdelmoneim 5; Ahmed M. Badawi 5; khalaf Hamead 6
| ||||
| 1Department of ENT , Faculty of medicine, Minina university | ||||
| 2department of pharmaceutics and clinical pharmacy deraya university | ||||
| 3otolaryngeology department, faculty of medicine,minia university | ||||
| 4Otorhinolaryngology department faculty of medicine minia university | ||||
| 5Department of ENT, Faculty of Medicine, Minia University | ||||
| 6otorhinolaryngology department ,faculty of medicine, Minia university | ||||
| Abstract | ||||
| Background: Olfactory dysfunction associated with COVID-19 is a significant issue that impairs quality of life. We address the potential of intranasal insulin as a therapeutic agent considering the limitation of viable medicines for this issue. Aim of the study: Assessment of intranasal insulin's therapeutic impact on post-COVID-19 Olfactory Dysfunction. Methodology: This study included 40 patients suffering from post-COVID-19 olfactory dysfunction at the ENT outpatient clinic of Minia University Hospital. They were divided into two groups: group 1 included 20 patients who received intranasal insulin fast-dissolving films while group 2 included 20 patients who received plain intranasal films (placebo). Results: The mean score of the Butanol threshold test for the intervention group was 3.4 while for the placebo group was 2.4 after the fourth session and the mean scores reached 5.7 for the intervention group and 2.6 for the placebo group after the eighth session reflecting a statistically significant improvement in olfactory function for the intervention group than the placebo group. Conclusion: Finally, our results showed that administering intranasal insulin to patients greatly shortened their anosmia duration. Notably, a highly statistically significant rise in Butanol Threshold test scores compared to pre-treatment scores highlights the potential advantages of intranasal insulin in treating olfactory impairment in patients who have recovered from COVID-19. | ||||
| Keywords | ||||
| Intranasal insulin; postCOVID-19; olfactory dysfunction; intranasal; fast dissolving film | ||||
|
Statistics Article View: 27 |
||||
